TABLE 1.
Therapeutic class | Mechanism | Molecules/pathways |
---|---|---|
Tyrosine kinase inhibitors | Inhibit receptor signalling | TGF-β, PDGF, VEGF, FGF, angiopoietin |
Src kinase inhibitors | Inhibit profibrotic signalling downstream of receptors | TGF-β, PDGF |
Histone deacetylase inhibitors | Prevent nuclear translocation and DNA binding of Smads | TGF-β, PDGF |
Monoclonal antibodies/blocking peptides | Directly bind to growth factors or block receptor ligation binding | TGF-β, PDGF, IGF-1, FGF, angiopoietin |
Activating peptides | Inhibit synthesis of matrix proteins | Relaxins, endostatin |
TGF: transforming growth factor; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor; FGF: fibroblast growth factor; IGF: insulin-like growth factor.